Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(62.5%)
Phase 3
3(37.5%)
8Total
Phase 2(5)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT00646425Phase 2Terminated

The Safety and Efficacy of Basiliximab as Maintenance Therapy in Subjects With Stable, Noninfectious Uveitis

Role: lead

NCT00931866Phase 3Completed

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)

Role: lead

NCT01061996Phase 2Terminated

Basiliximab Maintenance in Ulcerative Colitis

Role: lead

NCT00869063Phase 3Completed

Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion

Role: lead

NCT00869180Phase 3Completed

Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain

Role: lead

NCT00430898Phase 2Completed

Basiliximab in Moderate to Severe Ulcerative Colitis

Role: lead

NCT00640705Phase 2Terminated

Diclofenac Patch for Treatment of Mild to Moderate Ankle Sprain

Role: lead

NCT00640939Phase 2Completed

Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis

Role: lead

All 8 trials loaded